Rate of adverse event (AE) groups per 100 patient-years (py)*
| All patients | RA | PMR | IBD | |||||
| AE rate (AE/100 py (95 CI)) | Percentage of total | AE rate (AE/100 py (95 CI)) | Percentage of total | AE rate (AE/100 py (95 CI)) | Percentage of total | AE rate (AE/100 py (95 CI)) | Percentage of total | |
| Psychological and behavioural disturbances | 25 (15 to 34) | 20 | 19 (4 to 34) | 31 | 4 (−1 to 10) | 6 | 65 (37 to 93) | 8 |
| Gastrointestinal | 19 (14 to 24) | 15 | 5 (3 to 8) | 9 | 14 (5 to 22) | 18 | 169 (118 to 220) | 21 |
| Dermatological | 15 (10 to 20) | 12 | 6 (2 to 11) | 11 | 2 (0 to 5) | 3 | 107 (65 to 148) | 13 |
| Neurological | 12 (6 to 19) | 10 | 1 (0 to 1) | 1 | × | 140 (73 to 207) | 17 | |
| Musculoskeletal | 12 (7 to 17) | 9 | 4 (2 to 7) | 7 | 6 (2 to 11) | 8 | 113 (61 to 166) | 14 |
| Infectious | 12 (8 to 16) | 9 | 4 2 to 7) | 8 | 11 (7 to 15) | 14 | 58 (21 to 95) | 7 |
| Endocrine and metabolic | 11 (7 to 14) | 8 | 4 (2 to 6) | 6 | 12 (2 to 23) | 16 | 120 (74 to 166) | 15 |
| Cardiovascular | 8 (5 to 11) | 7 | 6 (2 to 11) | 11 | 12 (4 to 21) | 16 | 13 (2 to 25) | 2 |
| Other† | 8 (5 to 11) | 7 | 6 (2 to 10) | 10 | 12 (−2 to 26) | 15 | 16 (3 to 28) | 2 |
| Ophthalmological | 3 (2 to 4) | 3 | 4 (2 to 5) | 6 | 3 (−1 to 6) | 4 | × | |
*AE groups as defined in box 1, ranked.
†Microhaematuria, proteinuria, dysuria, episodes of salivary gland enlargement, pain, tremor, leucopenia, thrombocytopenia, other haematological AE, elevated liver enzymes, taste disturbance, “serious adverse events”, cervix carcinoma, carcinoma, death by cancer.
IBD, inflammatory bowel disease; PMR, polymyalgia rheumatica; RA, rheumatoid arthritis.